These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 30661095

  • 1. Influence of oral magnesium-containing supplement and antacid administration on hypomagnesemia induced by panitumumab.
    Sato J, Ishikawa H, Tanaka R, Sino M.
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):673-679. PubMed ID: 30661095
    [Abstract] [Full Text] [Related]

  • 2. Effect of proton pump inhibitors on the development of hypomagnesemia induced by panitumumab.
    Morii Y, Fujimoto S, Nakahara R, Okawa K, Senaha H, Fujiwara K, Tsubaki M, Matzno S, Takegami M, Shimomura K, Nishida S.
    Pharmazie; 2022 Feb 01; 77(2):81-84. PubMed ID: 35209968
    [Abstract] [Full Text] [Related]

  • 3. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
    Kimura M, Usami E, Teramachi H, Yoshimura T.
    Cancer Chemother Pharmacol; 2020 Sep 01; 86(3):383-391. PubMed ID: 32789758
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Effects of Oral Magnesium and Antacid Administration on Serum Magnesium Levels and Renal Function in Patients Receiving Cisplatin].
    Kamo Y, Sato J, Tanaka R, Shino M.
    Gan To Kagaku Ryoho; 2020 Apr 01; 47(4):605-608. PubMed ID: 32389961
    [Abstract] [Full Text] [Related]

  • 6. The association of proton pump inhibitors and hypomagnesemia in the community setting.
    Markovits N, Loebstein R, Halkin H, Bialik M, Landes-Westerman J, Lomnicky J, Kurnik D.
    J Clin Pharmacol; 2014 Aug 01; 54(8):889-95. PubMed ID: 24771616
    [Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor inhibitor-induced hypomagnesemia: a survey of practice patterns among Canadian gastrointestinal medical oncologists.
    Thangarasa T, Gotfrit J, Goodwin RA, Tang PA, Clemons M, Imbulgoda A, Vickers MM.
    Curr Oncol; 2019 Apr 01; 26(2):e162-e166. PubMed ID: 31043822
    [Abstract] [Full Text] [Related]

  • 8. Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?
    Abu-Amna M, Bar-Sela G.
    Cancer Chemother Pharmacol; 2019 Mar 01; 83(3):545-550. PubMed ID: 30547192
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
    Fujii H, Iihara H, Ishihara M, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y.
    Gan To Kagaku Ryoho; 2016 Feb 01; 43(2):229-33. PubMed ID: 27067688
    [Abstract] [Full Text] [Related]

  • 11. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
    Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, Franco OH, Kuipers EJ, Hofman A, Zietse R, Stricker BH, Hoorn EJ.
    Am J Kidney Dis; 2015 Nov 01; 66(5):775-82. PubMed ID: 26123862
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [The treatment of hypomagnesemia].
    van der Sijs IH, Ho-Dac-Pannekeet MM.
    Ned Tijdschr Geneeskd; 2002 May 18; 146(20):934-8. PubMed ID: 12051060
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
    Fujii H, Iihara H, Suzuki A, Kobayashi R, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y.
    Cancer Chemother Pharmacol; 2016 Jun 18; 77(6):1209-15. PubMed ID: 27106835
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients.
    Recart DA, Ferraris A, Petriglieri CI, Alonso Serena M, Bonella MB, Posadas-Martinez ML.
    Intern Emerg Med; 2021 Apr 18; 16(3):711-717. PubMed ID: 33001349
    [Abstract] [Full Text] [Related]

  • 20. Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication.
    Semb S, Helgstrand F, Hjørne F, Bytzer P.
    World J Gastroenterol; 2017 Oct 07; 23(37):6907-6910. PubMed ID: 29085234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.